HKSE · 1801.HK
Innovent Biologics, Inc.
HK$81.95+HK$0.35 (+0.43%)
Innovent Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.28% below the high.
Loading market information…
HKSE · 9688.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 03:28 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Zai Lab Limited’s quoted price sits in the upper half of its reported 52-week range, 18.07% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Zai Lab Limited’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -HK$0.43. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Zai Lab Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Zai Lab Limited, established in 2013 and based in Shanghai, China, is a biopharmaceutical company dedicated to developing and bringing to market innovative medical treatments. Its core focus spans oncology, autoimmune diseases, infectious diseases, and neurological conditions, primarily serving patients in Mainland China and Hong Kong. The company's portfolio of commercialized products includes Zejula, an oral, once-daily poly polymerase 1/2 inhibitor; Optune, a non-invasive device employing tumor treating fields; NUZYRA for addressing acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors. Zai Lab also maintains a robust pipeline of investigational therapies. This pipeline features numerous oncology assets such as Odronextamab for various lymphomas, Repotrectinib—a tyrosine kinase inhibitor targeting ROS1 and TRK fusions, Margetuximab for breast and gastroesophageal cancers, Adagrasib for KRAS-G12C-mutated solid tumors, and Bemarituzumab for gastric and gastroesophageal junction cancers. Other notable pipeline candidates include CLN-081 for specific non-small cell lung cancers, multi-targeted kinase inhibitors like Elzovantinib, several monoclonal antibodies (e.g., Tebotelimab, Retifanlimab, ZL-1201), and immune modulators such as Efgartigimod for reducing disease-causing IgG antibodies and ZL-1102 targeting IL-17A. Additionally, the company is advancing therapies like KarXT for psychiatric and neurological disorders, novel EGFR inhibitors (ZL-2313, ZL-2314), a CDC7 kinase inhibitor (ZL-2309), and Sulbactam/durlobactam for serious Acinetobacter infections, showcasing its commitment to a broad range of therapeutic innovations.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | -HK$0.35+18.03% vs estimate | HK$827.78M-3.94% vs estimate |
|---|
| Q4 2024 | Feb 27, 2025 | -HK$0.62-22.25% vs estimate | HK$848.02M+0.42% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -HK$0.33+47.18% vs estimate | HK$795.51M+0.71% vs estimate |
|---|
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$81.95+HK$0.35 (+0.43%)
Innovent Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.28% below the high.
HK$437.80HK$0.00 (0.0%)
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 22.17% below the high.
HK$83.45-HK$0.05 (-0.06%)
Akeso, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.51% below the high.
HK$13.74-HK$0.01 (-0.07%)
3SBio Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.21% below the high.
HK$49.68-HK$0.24 (-0.48%)
Shanghai Henlius Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.96% below the high.
HK$21.12-HK$0.04 (-0.19%)
HUTCHMED (China) Limited’s quoted price sits in the upper half of its reported 52-week range, 17.44% below the high.
HK$11.46-HK$0.21 (-1.8%)
InnoCare Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 29.26% below the high.
HK$27.98-HK$0.24 (-0.85%)
Ascentage Pharma Group International’s quoted price sits in the lower half of its reported 52-week range, 59.65% below the high.
